ArticleCureus2025
Retrospective Evaluation of Early Glargine Administration in Adults With Diabetic Ketoacidosis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose Diabetic ketoacidosis (DKA) is a life-threatening condition, and treatment consists of aggressive fluid replacement and correcting the insulin deficit to resolve the acidosis and hyperglycemia. American Diabetes Association (ADA) guidelines recommend administering insulin glargine after resolution. The purpose of this retrospective study was to determine if early glargine, given within six hours of starting insulin infusion, decreased insulin infusion time in patients admitted to the hospital with DKA. Methods Patients admitted to our hospital in 2021 with a diagnosis of DKA who were treated with an insulin drip were analyzed. Rebound hyperglycemia was analyzed using Pearson's chi-squared test. Stepwise linear regression analysis was performed for the primary outcome, insulin duration, and the main predictor was early versus late glargine. Results Duration of insulin infusion was shorter in the early glargine group (p=.043). There was a higher incidence of rebound hyperglycemia (>180 mg/dL) in the six hours after insulin discontinuation in the late glargine group, 63 (83%) vs. 35 (50%) (p<0.001). An interaction between early glargine and type 1 diabetes was significant (p=0.047), with analysis showing that early glargine did not reduce the infusion duration in type 1 diabetes but significantly reduced the duration in patients without type 1 diabetes (p=0.010). Conclusion Early glargine administration can decrease morbidity from rebound hyperglycemia and reduce the cost of care by minimizing the amount of time required to be on an insulin drip in a critical care setting. This effect was only found in individuals without type 1 diabetes, which may require further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.